Karin Havenith

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology · 2021 · 397 citations

Loncastuximab Tesirine, Lymphoid Neoplasia, Hematological Malignancy +6

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella et al. · Blood · 2020 · 165 citations · Full text

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Brad S. Kahl, Mehdi Hamadani, John Radford et al. · Clinical Cancer Research · 2019 · 102 citations

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi et al. · The Lancet Haematology · 2021 · 84 citations · Full text

Lymphoid Neoplasia, Medicine, Camidanlumab Tesirine +6

CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

Francesca Zammarchi, Karin Havenith, François Bertelli et al. · Journal for ImmunoTherapy of Cancer · 2020 · 77 citations · Full text